BlackRock Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlackRock Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-55	Closed	-$6K	–	4141
2016 Q1	$6K	Buy	55 +1	+2%	+$152	﹤0.01%	3781
2015 Q4	$10K	Buy	54 +5	+10%	+$935	﹤0.01%	3689
2015 Q3	$8K	Hold	49	–	–	﹤0.01%	3791
2015 Q2	$31K	Sell	49 -734	-94%	-$390K	﹤0.01%	3353
2015 Q1	$403K	Buy	783 +92	+13%	+$46.4K	﹤0.01%	3040
2014 Q4	$370K	Buy	691 +2	+0.3%	+$901	﹤0.01%	3126
2014 Q3	$1.03M	Buy	689 +10	+1%	+$14.5K	﹤0.01%	2502
2014 Q2	$930K	Buy	679 +187	+38%	+$217K	﹤0.01%	2656
2014 Q1	$684K	Buy	492 +65	+15%	+$75.6K	﹤0.01%	2779
2013 Q4	$425K	Sell	427 -13	-3%	-$13.4K	﹤0.01%	3022
2013 Q3	$458K	Buy	440 +34	+8%	+$36.3K	﹤0.01%	2969
2013 Q2	$442K	Buy	+406	New	+$452K	﹤0.01%	2919

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

BlackRock Investment Management's VIRX Position: Q2 2016 in Review

BlackRock Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2016, closing a stake of 55 shares — an estimated $6K sold.

BlackRock Investment Management first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $1.03M in Q3 2014. 56 funds tracked by Wall St. Rank hold VIRX as of Q2 2016.

BlackRock Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
BlackRock Investment Management sold 55 Viracta Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $6K.
BlackRock Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
BlackRock Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.03M in Q3 2014.
56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.